Literature DB >> 19166659

Nonalcoholic fatty liver disease and cardiovascular risk.

Vijay Laxmi Misra1, Mouen Khashab, Naga Chalasani.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a very common cause of chronic liver disease in the United States. A large proportion of patients with NAFLD have coexisting metabolic syndrome, a major risk factor for cardiovascular disease. A strong association between NAFLD and cardiovascular disease has been long suspected, and recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. NAFLD may pose cardiovascular risk beyond the risk conferred by traditional factors such as dyslipidemia, diabetes, and smoking. Health care providers managing patients with NAFLD should recognize this increased cardiovascular risk and should undertake early, aggressive risk factor modification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19166659      PMCID: PMC2732016          DOI: 10.1007/s11894-009-0008-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  53 in total

1.  Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Authors:  Jeffrey D Browning
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

2.  Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins.

Authors:  Carey N Lumeng; Stephanie M Deyoung; Alan R Saltiel
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-22       Impact factor: 4.310

Review 3.  Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.

Authors:  Giovanni Targher; Guido Arcaro
Journal:  Atherosclerosis       Date:  2006-09-12       Impact factor: 5.162

4.  Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States.

Authors:  George N Ioannou; Noel S Weiss; Edward J Boyko; Dariush Mozaffarian; Sum P Lee
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

5.  Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.

Authors:  Carlos K Furuya; Claudia P M S de Oliveira; Evandro S de Mello; Joel Faintuch; Alessandra Raskovski; Mitsunori Matsuda; Denise C P Vezozzo; Alfredo Halpern; Arthur B Garrido; Venâncio A F Alves; Flair J Carrilho
Journal:  J Gastroenterol Hepatol       Date:  2007-04       Impact factor: 4.029

6.  Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Authors:  John B Buse; David C Klonoff; Loretta L Nielsen; Xuesong Guan; Christopher L Bowlus; John H Holcombe; David G Maggs; Matthew E Wintle
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

7.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

8.  Long-term follow-up of patients with NAFLD and elevated liver enzymes.

Authors:  Mattias Ekstedt; Lennart E Franzén; Ulrik L Mathiesen; Lars Thorelius; Marika Holmqvist; Göran Bodemar; Stergios Kechagias
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

9.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis.

Authors:  Andrea Galassi; Kristi Reynolds; Jiang He
Journal:  Am J Med       Date:  2006-10       Impact factor: 4.965

10.  TNF-alpha alters visfatin and adiponectin levels in human fat.

Authors:  J Hector; B Schwarzloh; J Goehring; T G Strate; U F Hess; G Deuretzbacher; N Hansen-Algenstaedt; F-U Beil; P Algenstaedt
Journal:  Horm Metab Res       Date:  2007-04       Impact factor: 2.936

View more
  38 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

2.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

Authors:  G Targher; L Bertolini; M Chonchol; S Rodella; G Zoppini; G Lippi; L Zenari; E Bonora
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

3.  Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.

Authors:  David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-09-04       Impact factor: 3.619

4.  The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure.

Authors:  Tetsuya Takahashi; Tetsu Watanabe; Tetsuro Shishido; Ken Watanabe; Takayuki Sugai; Taku Toshima; Daisuke Kinoshita; Miyuki Yokoyama; Harutoshi Tamura; Satoshi Nishiyama; Takanori Arimoto; Hiroki Takahashi; Tamon Yamanaka; Takuya Miyamoto; Isao Kubota
Journal:  Heart Vessels       Date:  2017-12-29       Impact factor: 2.037

Review 5.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

6.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 7.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 8.  Metabolic syndrome and hepatic resection: improving outcome.

Authors:  Shefali Agrawal; Cherag Daruwala
Journal:  HPB (Oxford)       Date:  2011-10-19       Impact factor: 3.647

Review 9.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 10.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.